All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F14%3A10284268" target="_blank" >RIV/00216208:11110/14:10284268 - isvavai.cz</a>

  • Alternative codes found

    RIV/61383082:_____/14:#0000270

  • Result on the web

    <a href="http://dx.doi.org/10.1136/gutjnl-2013-305667" target="_blank" >http://dx.doi.org/10.1136/gutjnl-2013-305667</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1136/gutjnl-2013-305667" target="_blank" >10.1136/gutjnl-2013-305667</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C

  • Original language description

    Background and aim Severe adverse events (AEs) compromise the outcome of direct antiviral agent-based treatment in patients with advanced liver fibrosis due to HCV infection. HEP3002 is an ongoing multinational programme to evaluate safety and efficacy of telaprevir (TVR) plus pegylated-interferon-alpha (PEG-IFN alpha) and ribavirin (RBV) in patients with advanced liver fibrosis caused by HCV genotype 1 (HCV-1). Methods 1782 patients with HCV-1 and bridging fibrosis or compensated cirrhosis were prospectively recruited from 16 countries worldwide, and treated with 12 weeks of TVR plus PEG-IFN/RBV, followed by 12 or 36 weeks of PEG-IFN and RBV (PR) alone dependent on virological response to treatment and previous response type. Results 1587 patients completed 12 weeks of triple therapy and 4 weeks of PR tail (53% cirrhosis, 22% HCV-1a). By week 12, HCV RNA was undetectable in 85% of naives, 88% of relapsers, 80% of partial responders and 72% of null responders. Overall, 931 patients (59

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

  • CEP classification

    FE - Other fields of internal medicine

  • OECD FORD branch

Result continuities

  • Project

  • Continuities

    N - Vyzkumna aktivita podporovana z neverejnych zdroju

Others

  • Publication year

    2014

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Gut

  • ISSN

    0017-5749

  • e-ISSN

  • Volume of the periodical

    63

  • Issue of the periodical within the volume

    7

  • Country of publishing house

    GB - UNITED KINGDOM

  • Number of pages

    9

  • Pages from-to

    1150-1158

  • UT code for WoS article

    000337917900017

  • EID of the result in the Scopus database